NATIONAL INSTITUTES OF HEALTH
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
- Conditions
- Non-Hodgkin's LymphomaDiffuse Large B-Cell LymphomaDLBCLNHL
- Interventions
- First Posted Date
- 2019-07-01
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 132
- Registration Number
- NCT04002947
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
- Conditions
- Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedDiffuse Large B-Cell LymphomaDouble-Expressor LymphomaEBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsHigh Grade B-Cell Lymphoma, Not Otherwise SpecifiedNeoplastic Cells With Double Expression of MYC and BCL2 Proteins PresentTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow BiopsyProcedure: Computed TomographyProcedure: Lumbar PunctureProcedure: Positron Emission Tomography
- First Posted Date
- 2019-06-13
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 363
- Registration Number
- NCT03984448
- Locations
- 🇺🇸
OSF Saint Francis Medical Center, Peoria, Illinois, United States
🇺🇸Illinois CancerCare-Peru, Peru, Illinois, United States
🇺🇸Valley Radiation Oncology, Peru, Illinois, United States
Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow BiopsyProcedure: Echocardiogram RecordingProcedure: Multigated Acquisition Scan
- First Posted Date
- 2019-06-12
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT03983824
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Optimizing PTCy Dose and Timing
- Conditions
- Hematologic NeoplasmsGraft Versus Host Disease
- Interventions
- First Posted Date
- 2019-06-12
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 400
- Registration Number
- NCT03983850
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer
- First Posted Date
- 2019-06-06
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 175
- Registration Number
- NCT03976843
- Locations
- 🇺🇸
Tulane University, New Orleans, Louisiana, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy
- Conditions
- Metastatic Lung Non-Squamous Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8Unresectable Lung Non-Small Cell CarcinomaUnresectable Lung Non-Squamous Non-Small Cell CarcinomaStage IIIB Lung Cancer AJCC v8Stage IVB Lung Cancer AJCC v8Metastatic Lung Non-Small Cell Squamous CarcinomaStage IVA Lung Cancer AJCC v8
- Interventions
- First Posted Date
- 2019-05-29
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 27
- Registration Number
- NCT03965689
- Locations
- 🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)
- Conditions
- Central Nervous System LymphomaSecondary Central Nervous System Lymphoma
- Interventions
- First Posted Date
- 2019-05-28
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT03964090
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma
- Conditions
- Myeloma, Plasma-CellMyeloma-Multiple
- Interventions
- Biological: Anti-Signaling lymphocytic activation molecule F7 (SLAMF7) chimeric antigen receptor (CAR) T cells
- First Posted Date
- 2019-05-22
- Last Posted Date
- 2021-09-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 13
- Registration Number
- NCT03958656
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation
- Conditions
- Recurrent Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia Post Cytotoxic TherapyRecurrent Myelodysplastic SyndromeRefractory Acute Myeloid LeukemiaRefractory Myelodysplastic SyndromeAcute Myeloid Leukemia
- Interventions
- First Posted Date
- 2019-05-17
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 14
- Registration Number
- NCT03953898
- Locations
- 🇺🇸
Wake Forest University at Clemmons, Clemmons, North Carolina, United States
🇺🇸UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States
De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
- Conditions
- Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Oropharyngeal Squamous Cell CarcinomaBasaloid Squamous Cell CarcinomaClinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Papillary Squamous Cell CarcinomaSquamous Cell CarcinomaPathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Interventions
- Procedure: Biopsy ProcedureProcedure: Biospecimen CollectionProcedure: Computed TomographyOther: Fludeoxyglucose F-18Radiation: Image Guided Radiation TherapyRadiation: Intensity-Modulated Radiation TherapyProcedure: Positron Emission TomographyProcedure: Magnetic Resonance ImagingOther: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2019-05-16
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 384
- Registration Number
- NCT03952585
- Locations
- 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Banner University Medical Center - Tucson, Tucson, Arizona, United States